Sign In
Buy GLO
$5.84
+0.0200 (+0.344%)
At Close: Jul 31, 2026
Asia Has a Wild Tech Rally of Its Own
09:30am, Thursday, 06'th Aug 2020
This summer’s big rally in technology stocks hasn’t been limited to America. Shares of some Asian tech giants have also climbed to new heights, powering gains in major market indexes.
Clough Global Opportunities Fund Declares Monthly Cash Distributions For July, August, And September 2020 Of $0.0897 Per Share
10:00am, Friday, 10'th Jul 2020
Today, the Board of Trustees (the "Board") for the Clough Global Opportunities Fund (the "Fund") has declared a monthly cash distribution of $0.0897 per common share, payable on the dates noted below.
Clough Global Opportunities Fund Section 19(a) Notice
10:00am, Tuesday, 30'th Jun 2020
On June 30, 2020, the Clough Global Opportunities Fund (NYSE MKT: GLO) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0897 per share to shareholders of record a
The Board of Trustees of the Clough Global Dividend and Income Fund, Clough Global Equity Fund and Clough Global Opportunities Fund (each, a "Fund" and together, the "Funds") have determined it is adv
The Reopening Killed The V-Shaped Recovery
07:43am, Monday, 29'th Jun 2020
This is a weekly series focused on analyzing the previous week’s economic data releases. The objective is to concentrate on leading indicators of economic activ
Novo helps lead Checkmate Pharmaceuticals' $85M raise for single asset bet
11:30am, Thursday, 11'th Jun 2020
Next-gen cancer biotech Checkmate Pharmaceuticals has grabbed a healthy series C round toward work on its all-or-nothing immuno-oncology hopeful.
Clough Global Opportunities Fund Declares A Monthly Cash Distribution For April, May, And June 2020 Of $0.0897 Per Share
10:00am, Thursday, 09'th Apr 2020
Today, the Board of Trustees (the "Board") for the Clough Global Opportunities Fund (the "Fund") has declared a monthly cash distribution of $0.0897 per common share, payable on the dates noted below.
Looking For Yield - Meet The Blues Brothers
07:00am, Sunday, 23'rd Feb 2020
Coronavirus is infecting the bond markets. This could take yields down to places that have not been seen in recent memory. Last year the equity markets provided
Stellar Year For Income Factory's 'Widows And Orphans' Model Portfolio
05:28pm, Tuesday, 04'th Feb 2020
Widows & Orphans had a great year in 2019 as their less aggressive model Income Factory achieved a total return of 28%, with a distribution yield of 8%. Our mor
73 Dividend Boosts Declared January 20 And 27, 2020
02:20am, Thursday, 30'th Jan 2020
Barron's Weekly posts a list of stocks announcing dividend payment boosts on the very last page of its financial data section. Here is your dog catcher 1/20 - 1
Income Factory Return Of 24.5% Is Great, But The 12.75% Cash Distribution Really Excites Me
06:57pm, Thursday, 16'th Jan 2020
Back in 2018, we reported that paper losses had driven our 2018 total return down to -10%, but we were happily pocketing and reinvesting our 13% distribution yi
Clough Global Opportunities Fund Declares A Monthly Cash Distribution Of $0.0897 Per Share
11:00am, Friday, 10'th Jan 2020
Today, the Board of Trustees (the "Board") for the Clough Global Opportunities Fund (the "Fund") has declared a monthly cash distribution of $0.0897 per common share, payable on the dates noted below.
Clough Global Opportunities Fund Declares a Monthly Cash Distribution of $0.0852 Per Share
11:00am, Friday, 08'th Nov 2019
DENVER , Nov. 8, 2019 /PRNewswire/ -- Today, the Board of Trustees (the "Board") for the Clough Global Opportunities Fund (the "Fund") has declared a monthly cash distribution of $0.0852 ...
Apellis Pharmaceuticals Raises $60M in Series E Financing |FinSMEs
01:16pm, Thursday, 10'th Aug 2017
Apellis Pharmaceuticals, Inc., a Lousiville, Ky.-based clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, closed a
Sienna Biopharmaceuticals Completes $40M Series B Financing |FinSMEs
02:40pm, Monday, 24'th Apr 2017
Sienna Biopharmaceuticals, Inc., a Westlake Village, Calif.-based clinical stage medical dermatology and aesthetics company, completed a $40m Series B financing. The round was led by existing investor
